RecruitingPhase 1NCT06920238

Use of a Generative AI (Gen-AI) Chatbot for Anxiety and Depression Among Persons With Cannabis Use

A Phase I Single-Arm Trial to Test the Use of a Generative AI (Gen-AI) Chatbot for Anxiety and Depression Among Persons With Cannabis Use Disorder (CUD)

Sponsor

Trustees of Dartmouth College

Enrollment

15 participants

Start Date

Apr 13, 2025

Study Type

INTERVENTIONAL

Conditions

Depression, Anxiety Anxiety Depression - Major Depressive Disorder Cannabis Use Disorder

Summary

The goal of this clinical trial is to learn if Therabot-CALM (Cannabis, Anxiety, Low Mood) has acceptability among users and could work to improve the symptoms of persons with cannabis use disorder and anxiety and/or depression. The main question it aims to answer is: What is the usability, feasibility, and acceptability of Therabot-CALM in persons with Cannabis Use Disorder and Anxiety and/or Depression? Participants will * Take a screening questionnaire * Participate in two virtual 1-hour interviews to provide feedback on app design and suggest features. * Engage with Therabot-CALM in a 4-week clinical trial and provide feedback on their app experience in a third virtual interview

Eligibility

Min Age: 18 Years

Inclusion Criteria5

Is 18 years or older.
Meet criteria for current CUD (CUDIT-R\>=12) and MDD (PHQ-9\>=10), and/or GAD (GAD-7\>=10).
Have reliable access to the internet and a compatible device for Therabot-CALM.
Have willingness and capacity to provide informed consent and commit to participating in all assessments and interventions during the study.
Attend the first interview.

Exclusion Criteria3

Moderate to High risk of STBs as determined by the C-SSRS or baseline questionnaires.
Current psychosis (as determined by brief psychosis screen).
Current participation in another digital mental health intervention.

Interventions

DEVICETherabot-CALM

Therabot is a generative-AI-driven mobile app designed to provide mental health treatment. The feasibility of Therabot-CALM, an adapted Therabot application, is being tested for the future use of treating co-occurring substance use disorders and anxiety and/or depression. The primary purpose of this study is application feasibility.